Perspectives
"Enthusiasm for the host of clinical data released at the American Diabetes Association meeting has simmered down as the FDA’s long-term safety concerns will weigh heavily on whether these drugs will actually make it to market. New data on weekly versions of GLP-1’s, PhII data from Roche’s aleglitazar, and data for a novel class of drugs that aim to treat diabetes by blocking IL-1β were all important developments in the fight against diabetes, but what does it mean for their developers?" ... Read more
8 Jun 2009 | From the latest Perspectives entry by Vishal Manchanda, ADA Takes to the Streets in New Orleans
Research Library . Recent Updates
| 2 Jul 2009 | MYGN,Outperform , Stand Alone Diagnostic Business Will Not Disappoint » |
|---|---|
| 2 Jul 2009 | ACOR,BIIB,ELN, Fampridine SR Ex-US Partnership a Boost for Acorda and Complements BIIB MS Franchise! » |
| 1 Jul 2009 | Piramal Healthcare, Market Perform, Annual Report Review:-Investing Away From Contract Manufacturing » |
| 30 Jun 2009 | Chinese Health Reforms a Negative for Biopharma Investing » |
| 30 Jun 2009 | SUNPHARMA, Market Perform , USFDA’s Action SUNP’s Credibility At Stake » |
| 29 Jun 2009 | Novo To Gain From Sanofi Pains » |
